Apoquel 5.4mg Tablets 100 pack

   Product Ref: PFAPO06 Category: A

£ 108.51

Vat Rate: 20%

Prescription Required

Indicated for the treatment of pruritus associated with allergic dermatitis and the clinical manifestations of atopic dermatitis in dogs.
Vat Rate: 20%

Royal Mail 2nd Class / Parcel Force 48

UK to UK :Normally arrives in 2-4 business days.

UK to Ireland :Normally arrives in 4-6 business days

UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going


Please note standered delivery is none trackable , none insured , no responsabily for lose or Damage




Royal Mail First Class / Parcel Force 24

UK to UK :Normally arrives in 1-2 business days.

UK to Ireland 3-4 business days

UK to EU Countries : Normally arrives in 6-10 working days depending on where the parcel is going


Please note :Trackable , Royal Mail insured up to £50.



Parcel Force Express AM Guaranteed before Midday.

UK to UK only . UP to 5KG Max Weight

Arrives next day before 12 noon, requires a signature.


Parcel Forcel Terms & Conditions apply


Important: Parcel Force advise that there are some postcodes where an extended delivery time exists, and may affect the date of delivery or the service is not available.


You must be logged in to write review
Category POM-V
Temperature Ambient
MA/VM/EU No: EU/2/13/154/008
  • dog
VMD Link Product Information Database (defra.gov.uk)
NOAH Link https://www.noahcompendium.co.uk/?id=-456459
Dosage bcutaneous lumps 2.6% 2.7% 1.0% 0% Lethargy 2.0% 1.4% 1.8% 1.4% Polydipsia 0.7% 1.4% 1.4% 0% After day 16, the following adverse reactions have been observed: •pyoderma and non-specified dermal lumps have been observed very commonly; •otitis, vomiting, diarrhoea, histiocytoma, cystitis, yeast skin infections, pododermatitis, lipoma, polydipsia, lymphadenopathy, nausea, increased appetite and aggression have been observed commonly. The frequency of adverse reactions is defined using the following convention: •very common (more than 1 in 10 animals treated displaying adverse reaction(s)) •common (more than 1 but less than 10 animals in 100 animals treated) •uncommon (more than 1 but less than 10 animals in 1,000 animals treated) •rare (more than 1 but less than 10 animals in 10,000 animals treated) •very rare (less than 1 animal in 10,000 animals treated, including isolated reports). Treatment related clinical pathology changes were restricted to an increase in mean serum cholesterol and a decrease in mean leukocyte count, however, all mean values remained within the laboratory reference range. The decrease in mean leukocyte count observed in oclacitinib-treated dogs was not progressive, and affected all white blood cell counts (neutrophil, eosinophil and monocyte counts) except lymphocyte counts. Neither of these clinical pathology changes appeared clinically significant. The development of papillomas was noted in a number of dogs in a laboratory study. Anaemia and lymphoma have been reported very rarely in spontaneous reports. No drug interactions were observed in field studies where oclacitinib was administered concomitantly with veterinary medicinal products such as endo- and ectoparasiticides, antimicrobials and anti-inflammatories. The impact of oclacitinib administration on vaccination with modified live vaccines, canine parvovirus (CPV), canine distemper virus (CDV) and canine parainfluenza (CPI) and inactivated rabies vaccine (RV), on 16 week old vaccine naïve puppies has been studied. An adequate immune response (serology) to CDV and CPV vaccination was achieved when puppies were administered oclacitinib at 1.8 mg/kg bodyweight twice daily for 84 days. However, the findings of this study indicated a reduction in serological response to vaccination with CPI and RV in puppies being treated with oclacitinib compared to untreated controls. The clinical relevance of these observed effects for animals vaccinated while being administered oclacitinib (in accordance with the recommended dosing regimen) is unclear. Oclacitinib tablets were administered at 1x, 3x and 5x to healthy, one year old Beagle dogs twice daily for 6 weeks followed by once daily for 20 weeks. Clinical observations that were considered likely to be related to oclacitinib treatment included: alopecia (local), papilloma, dermatitis, erythema, abrasions and scabbing/crusts, interdigital "cysts", and oedema of the paws. Dermatitis lesions were mostly secondary to the development of interdigital furunculosis on one or more paws during the study, with the number and frequency of observations increased with increasing dose. Lymphadenopathy of peripheral nodes was noted in all groups, increasing in frequency with increased dose, and was frequently associated with interdigital furunculosis. Papilloma was considered treatment related, but not dose related. There is no specific antidote and in case of signs of overdose the dog should be treated symptomatically. User warnings Wash hands after administration. In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the doctor.